ZEPZELCA
Total Payments
$16.1M
Transactions
21,700
Doctors
6,678
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.1M | 6,295 | 3,277 |
| 2023 | $5.1M | 5,758 | 2,486 |
| 2022 | $5.1M | 4,592 | 2,324 |
| 2021 | $1.4M | 4,019 | 2,103 |
| 2020 | $305,780 | 1,036 | 734 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.1M | 2,256 | 68.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.8M | 865 | 17.3% |
| Consulting Fee | $828,198 | 278 | 5.1% |
| Food and Beverage | $502,192 | 16,909 | 3.1% |
| Travel and Lodging | $402,845 | 1,263 | 2.5% |
| Grant | $290,003 | 1 | 1.8% |
| Space rental or facility fees (teaching hospital only) | $231,850 | 68 | 1.4% |
| Education | $1,258 | 60 | 0.0% |
Payments by Type
Research
$11.1M
2,256 transactions
General
$5.0M
19,444 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 1B/2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA | JAZZ PHARMACEUTICALS INC. | $3.5M | 0 |
| EMERGE-201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF LURBINECTEDIN EFFICACY AND SAFETY IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | JAZZ PHARMACEUTICALS INC. | $1.5M | 0 |
| EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC) RECEIVING ZEPZELCA | JAZZ PHARMACEUTICALS INC. | $721,961 | 0 |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed, ?Refractory Ewing Sarcoma | JAZZ PHARMACEUTICALS INC. | $644,295 | 0 |
| EMERGE-201: A Phase 2, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced or Metastatic Solid Tumors | JAZZ PHARMACEUTICALS INC. | $640,043 | 0 |
| A Phase 1b/2 Trial of Lurbinectedin plus Doxorubicin in Leiomyosarcoma | JAZZ PHARMACEUTICALS INC. | $447,140 | 0 |
| PHASE I STUDY OF PALLIATIVE RADIOTHERAPY WITH LURBINECTEDIN IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | JAZZ PHARMACEUTICALS INC. | $376,978 | 0 |
| LURBINECTEDIN IN FET-FUSION TUMORS | JAZZ PHARMACEUTICALS INC. | $300,000 | 0 |
| LURBINECTEDIN IN FET-FUSION TUMORS (LIFFT) | JAZZ PHARMACEUTICALS INC. | $300,000 | 0 |
| The LiFFT Study (Lurbinectedin in FET-Fusion Tumors) | JAZZ PHARMACEUTICALS INC. | $300,000 | 0 |
| A PHASE II PILOT CLINICAL TRIAL OF LURBINECTEDIN ZEPZELCA PM01183 IN PATIENTS WITH ADVANCED PANCREATIC CANCER WITH DNA REPAIR MUTATIONS | JAZZ PHARMACEUTICALS INC. | $293,484 | 0 |
| ACTIVITY AND ENHANCEMENT OF IMMUNE CHECKPOINT INHIBITION WITH LURBINECTEDIN IN RELAPSED/RECURRENT SMALL CELL LUNG CANCER (SCLC) | JAZZ PHARMACEUTICALS INC. | $275,933 | 0 |
| PHASE 1B OF LURBINECTEDIN IN COMBINATION WITH WEEKLY PACLITAXEL AND BEVACIZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER | JAZZ PHARMACEUTICALS INC. | $274,346 | 0 |
| A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), RECOMMENDED PHASE 2 DOSE (RP2D), AND EFFICACY OF LURBINECTEDIN MONOTHERAPY IN PEDIATRIC PARTICIPANTS WITH PREVIOUSLY TREATED SOLID TUMORS FOLLOWED BY EXPANSION TO ASSESS EFFICACY AND SAFETY IN PEDIATRIC AND YOUNG ADULT PARTICIPANTS WITH RELAPSED/REFRACTORY EWING SARCOMA | JAZZ PHARMACEUTICALS INC. | $229,149 | 0 |
| EMERGE-201: A PHASE 2 MULTICENTER OPEN-LABEL STUDY OF LURBINECTEDIN EFFICACY AND SAFETY IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | JAZZ PHARMACEUTICALS INC. | $219,157 | 0 |
| IST 12327 - A Phase 1/2 Study of Safety/Efficacy Using LURBINECTEDIN, IPILIMUMAB, and NIVOLUMAB for Advanced Soft Tissue Sarcomas | JAZZ PHARMACEUTICALS INC. | $202,558 | 0 |
| LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN, COMBINED WITH IPILIMUMAB, AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMAS | JAZZ PHARMACEUTICALS INC. | $202,558 | 0 |
| EVALUATION OF THE EFFICACY AND IMMUNE MICROENVIRONMENTAL EFFECTS OF LURBINECTEDIN ALONE AND IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN SQUAMOUS CARCINOMA MODELS | JAZZ PHARMACEUTICALS INC. | $154,586 | 0 |
| EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | JAZZ PHARMACEUTICALS INC. | $126,666 | 0 |
| RAD5466-21 - A Pilot Study of Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer | JAZZ PHARMACEUTICALS INC. | $88,578 | 0 |
Top Doctors Receiving Payments for ZEPZELCA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Los Angeles, CA | $51,451 | 35 |
| , M.D | Hematology & Oncology | Ann Arbor, MI | $38,670 | 29 |
| , M.D., PH.D | Hematology & Oncology | New York, NY | $35,860 | 10 |
| , MD | Hematology & Oncology | Jersey City, NJ | $33,000 | 25 |
| , MD | Hematology & Oncology | Omaha, NE | $32,293 | 13 |
| , M.D | Internal Medicine | Mechanicsville, VA | $31,333 | 25 |
| , MD | Medical Oncology | Minneapolis, MN | $28,577 | 32 |
| , MD,PHD | Hematology & Oncology | Riverdale, GA | $27,981 | 29 |
| , M.D | Specialist | Philadelphia, PA | $24,797 | 7 |
| , M.D., PH.D | Medical Oncology | Milwaukee, WI | $24,779 | 15 |
| , M.D | Internal Medicine | Pascagoula, MS | $23,358 | 17 |
| , M.D. PH.D | Internal Medicine | Indianapolis, IN | $21,528 | 27 |
| , MD | Student in an Organized Health Care Education/Training Program | Nashville, TN | $20,648 | 11 |
| , NP-C | Family | Washington, DC | $20,430 | 59 |
| , MD | Internal Medicine | Burlington, MA | $19,539 | 10 |
| , M.D | Hematology & Oncology | Youngstown, OH | $18,785 | 19 |
| , MD, PHD | Critical Care Medicine | Murfreesboro, TN | $16,549 | 14 |
| , MD | Hematology & Oncology | Louisville, KY | $16,484 | 19 |
| , MD | Internal Medicine | Wichita, KS | $16,446 | 17 |
| , MD | Pediatric Hematology-Oncology | Houston, TX | $15,360 | 3 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $14,718 | 5 |
| , MD | Medical Oncology | New Haven, CT | $14,527 | 3 |
| , MD | Hematology & Oncology | Chandler, AZ | $14,111 | 12 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | Altamonte Springs, FL | $13,659 | 16 |
| , M.D | Hematology & Oncology | Long Beach, CA | $13,074 | 5 |
Ad
Manufacturing Companies
- JAZZ PHARMACEUTICALS INC. $15.5M
- Jazz Pharmaceuticals Inc. $634,315
Product Information
- Type Drug
- Total Payments $16.1M
- Total Doctors 6,678
- Transactions 21,700
About ZEPZELCA
ZEPZELCA is a drug associated with $16.1M in payments to 6,678 healthcare providers, recorded across 21,700 transactions in the CMS Open Payments database. The primary manufacturer is Jazz Pharmaceuticals Inc..
Payment data is available from 2020 to 2024. In 2024, $4.1M was paid across 6,295 transactions to 3,277 doctors.
The most common payment nature for ZEPZELCA is "Unspecified" ($11.1M, 68.7% of total).
ZEPZELCA is associated with 20 research studies, including "A PHASE 1B/2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA" ($3.5M).